The Journal of Advanced Prosthodontics

The Korean Academy of Prosthodonitics (대한치과보철학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of alendronate on bone remodeling around implant in the rat

  • Park, Ran (Department of Prosthodontics, Oral Science Research Center, Yonsei University College of Dentistry) ;
  • Kim, Jee-Hwan (Department of Prosthodontics, Oral Science Research Center, Yonsei University College of Dentistry) ;
  • Choi, Hyunmin (Department of Prosthodontics, Oral Science Research Center, Yonsei University College of Dentistry) ;
  • Park, Young-Bum (Department of Prosthodontics, Oral Science Research Center, Yonsei University College of Dentistry) ;
  • Jung, Han-Sung (Division in Anatomy and Developmental Biology, Department of Oral Biology, Oral Science Research Center, Yonsei University College of Dentistry) ;
  • Moon, Hong-Seok (Department of Prosthodontics, Oral Science Research Center, Yonsei University College of Dentistry)
  • Received : 2012.12.11
  • Accepted : 2013.04.22
  • Published : 2013.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

PURPOSE. The purpose of this study was to evaluate the effect of alendronates on bone remodeling around titanium implant in the maxilla of rats. MATERIALS AND METHODS. The maxillary first molars were extracted and customized-titanium implants were placed immediately in thirty male Sprague-Dawley rats. The rats were divided into experimental (bisphosphonate) group and control group. At 4 weeks after implantation, the rats in the bisphosphonate group were subcutaneously injected with alendronate three times a week for 6 weeks where as the rats in control group were injected with saline. The rats were sacrificed at 1, 2, 3, 4, or 6 weeks after starting of injection and maxillary bones were collected subsequently. Alveolar bone remodeling around the implants were evaluated by radiographic and histologic analysis. Microarray analysis and immunohistomorphologic analysis were also performed on one rat, sacrificed at 6 weeks after starting of injection, from each group. Statistical analysis was performed using repeated measures analysis of variance and independent t test at a significance level of 5%. RESULTS. There was no statistically significant difference in the bone area (%) around implant between the bisphosphonate group and the control group. However, the amount of empty lacuna was significantly increased in the bisphosphonate group, especially in the rats sacrificed at 4 weeks after starting of injection compared to that of the corresponding control group. The bisphosphonate group showed the same level of TRAP positive cell count, osteocalcin and angiopoietin 1 as the control group. CONCLUSION. Alendronate may not decrease the amount of osteoclast. However, the significantly increased amount of empty lacuna in the bisphosphonate group may explain the suppression of bone remodeling in the bisphosphonate group.

Keywords

References

  1. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008;83:1032-45. https://doi.org/10.4065/83.9.1032
  2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
  3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34. https://doi.org/10.1016/j.joms.2004.02.004
  4. Allen MR, Burr DB. The pathogenesis of bisphosphonaterelated osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009;67:61-70.
  5. Hikita H, Miyazawa K, Tabuchi M, Kimura M, Goto S. Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. J Bone Miner Metab 2009;27:663-72. https://doi.org/10.1007/s00774-009-0090-6
  6. Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto- Nakano M, Hata K, Yatani H, Yoneda T. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab 2010; 28:165-75. https://doi.org/10.1007/s00774-009-0128-9
  7. Lazarovici TS, Yahalom R, Taicher S, Schwartz-Arad D, Peleg O, Yarom N. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010;68:790-6. https://doi.org/10.1016/j.joms.2009.09.017
  8. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 2008;66: 223-30. https://doi.org/10.1016/j.joms.2007.09.019
  9. Smith SY, Recker RR, Hannan M, Müller R, Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003;32:45-55. https://doi.org/10.1016/S8756-3282(02)00923-7
  10. Allen MR, Kubek DJ, Burr DB. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res 2010;25:98-105. https://doi.org/10.1359/jbmr.090713
  11. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007;86:1013-21. https://doi.org/10.1177/154405910708601101
  12. Futami T, Fujii N, Ohnishi H, Taguchi N, Kusakari H, Ohshima H, Maeda T. Tissue response to titanium implants in the rat maxilla: ultrastructural and histochemical observations of the bone-titanium interface. J Periodontol 2000;71: 287-98. https://doi.org/10.1902/jop.2000.71.2.287
  13. Listgarten MA. Soft and hard tissue response to endosseous dental implants. Anat Rec 1996;245:410-25. https://doi.org/10.1002/(SICI)1097-0185(199606)245:2<410::AID-AR20>3.0.CO;2-R
  14. Masuda T, Yliheikkilä PK, Felton DA, Cooper LF. Generalizations regarding the process and phenomenon of osseointegration. Part I. In vivo studies. Int J Oral Maxillofac Implants 1998;13:17-29.
  15. Pereira MC, Zecchin KG, Campagnoli EB, Jorge J. Ovariectomy delays alveolar wound healing after molar extractions in rats. J Oral Maxillofac Surg 2007;65:2248-53. https://doi.org/10.1016/j.joms.2006.11.040
  16. Fujii N, Kusakari H, Maeda T. A histological study on tissue responses to titanium implantation in rat maxilla: the process of epithelial regeneration and bone reaction. J Periodontol 1998;69:485-95. https://doi.org/10.1902/jop.1998.69.4.485
  17. Karimbux NY, Sirakian A, Weber HP, Nishimura I. A new animal model for molecular biological analysis of the implant- tissue interface: spatial expression of type XII collagen mRNA around a titanium oral implant. J Oral Implantol 1995;21:107-13; discussion 114-5.
  18. Shimizu M, Sasaki T, Ishihara A, Furuya R, Kawawa T. Bone wound healing after maxillary molar extraction in ovariectomized aged rats. J Electron Microsc (Tokyo) 1998;47:517-26. https://doi.org/10.1093/oxfordjournals.jmicro.a023623
  19. Bi Y, Gao Y, Ehirchiou D, Cao C, Kikuiri T, Le A, Shi S, Zhang L. Bisphosphonates cause osteonecrosis of the jawlike disease in mice. Am J Pathol 2010;177:280-90. https://doi.org/10.2353/ajpath.2010.090592
  20. Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y, Chen C, Chen W, Wang S, Le AD, Shi S. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonaterelated osteonecrosis of the jaw-like disease in mice. J Bone Miner Res 2010;25:1668-79. https://doi.org/10.1002/jbmr.37
  21. Mashiba T, Turner CH, Hirano T, Forwood MR, Jacob DS, Johnston CC, Burr DB. Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone 2001;29:271-8. https://doi.org/10.1016/S8756-3282(01)00575-0
  22. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28:524-31. https://doi.org/10.1016/S8756-3282(01)00414-8
  23. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-63. https://doi.org/10.1056/NEJMoa023110
  24. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301. https://doi.org/10.1210/jc.2004-0952
  25. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008;93:2948-52. https://doi.org/10.1210/jc.2007-2803
  26. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-78. https://doi.org/10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L
  27. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119:S150-62. https://doi.org/10.1542/peds.2006-2023H
  28. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100. https://doi.org/10.1210/edrv.19.1.0325
  29. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993;92:2577-86. https://doi.org/10.1172/JCI116872
  30. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80. https://doi.org/10.1172/JCI119668
  31. Yang Li C, Majeska RJ, Laudier DM, Mann R, Schaffler MB. High-dose risedronate treatment partially preserves cancellous bone mass and microarchitecture during long-term disuse. Bone 2005;37:287-95. https://doi.org/10.1016/j.bone.2005.04.041
  32. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009;360:53-62. https://doi.org/10.1056/NEJMoa0802633
  33. Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 2001;16:1575-82. https://doi.org/10.1359/jbmr.2001.16.9.1575
  34. Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H. Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab 2008;26:260-4. https://doi.org/10.1007/s00774-007-0823-3
  35. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61. https://doi.org/10.1124/jpet.102.035295
  36. Rubin CT, Bain SD, McLeod KJ. Suppression of the osteogenic response in the aging skeleton. Calcif Tissue Int 1992; 50:306-13. https://doi.org/10.1007/BF00301627
  37. Klein-Nulend J, Sterck JG, Semeins CM, Lips P, Joldersma M, Baart JA, Burger EH. Donor age and mechanosensitivity of human bone cells. Osteoporos Int 2002;13:137-46. https://doi.org/10.1007/s001980200005

Cited by

  1. Evaluation of the first maxillary molar post-extraction socket as a model for dental implant osseointegration research vol.27, pp.12, 2015, https://doi.org/10.1111/clr.12571
  2. Effects of Bisphosphonate Administration on Cleft Bone Graft in a Rat Model vol.54, pp.6, 2017, https://doi.org/10.1597/15-356
  3. Tibolone, alendronate, and simvastatin enhance implant osseointegration in a preclinical in vivo model vol.31, pp.7, 2013, https://doi.org/10.1111/clr.13602